SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and
cognition in patients with mild to moderate Alzheimer's disease.